Vol. 11, No. 3, 2011
Issue release date: September 2011
Free Access
Pancreatology 2011;11:343–350
(DOI:10.1159/000329183)
Original Paper
Add to my selection

Elevated microRNA miR-21 Levels in Pancreatic Cyst Fluid Are Predictive of Mucinous Precursor Lesions of Ductal Adenocarcinoma

Ryu J.K.a, e · Matthaei H.a · dal Molin M.a · Hong S.-M.a · Canto M.I.b · Schulick R.D.c, d · Wolfgang C.c · Goggins M.G.a, b, d · Hruban R.H.a, d · Cope L.d · Maitra A.a, d
Departments of aPathology, bMedicine, cSurgery and dOncology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, Md., USA; eDepartment of Internal Medicine, Seoul National University School of Medicine, Seoul, South Korea
email Corresponding Author


 Outline


 goto top of outline Key Words

  • Pancreatic cyst
  • Intraductal papillary mucinous neoplasm
  • Mucinous cystic neoplasm
  • microRNA
  • Biomarker

 goto top of outline Abstract

Background: Biomarkers for the diagnostic classification of pancreatic cysts are urgently needed. Deregulated microRNA (miRNAs) expression is widespread in pancreatic cancer. We assessed whether aberrant miRNAs in pancreatic cyst fluid could be used as potential biomarkers for cystic precursor lesions of pancreatic cancer. Methods: Cyst fluid specimens were prospectively collected from 40 surgically resected pancreatic cysts, and small RNAs were extracted. The ‘mucinous’ cohort included 14 intraductal papillary mucinous neoplasms (including 3 with an associated adenocarcinoma) and 10 mucinous cystic neoplasms; the ‘nonmucinous’ cohort included 11 serous cystadenomas and 5 other benign cysts. Quantitative reverse transcription PCR was performed for five miRNAs (miR-21, miR-155, miR-221, miR-17-3p, miR-191), which were previously reported as overexpressed in pancreatic adenocarcinomas. Results: Significantly higher expression of miR-21, miR-221, and miR-17-3p was observed in the mucinous versus nonmucinous cysts (p < 0.01), with the mean relative fold differences being 7.0-, 7.9-, and 5.4-fold, respectively. Receiver operating characteristic curves demonstrated the highest median area under the curve for miR-21, with a median specificity of 76%, at a sensitivity of 80%. Conclusion: This pilot study demonstrates that profiling miRNAs in pancreatic cyst fluid samples is feasible and can yield potential biomarkers for the classification of cystic lesions of the pancreas.

Copyright © 2011 S. Karger AG, Basel and IAP


goto top of outline Introduction

Pancreatic adenocarcinoma (aka pancreatic cancer) is an almost uniformly fatal disease, which claims the lives of >37,000 Americans each year [1]. The overwhelming majority of patients with pancreatic cancer presents with surgically inoperable disease, such that the only options available remain systemic chemotherapy, which has proven to have minimal efficacy [2]. Therefore, the best hope for ameliorating the dismal prognosis of pancreatic cancer rests on its early detection at an operable, and hence, potentially curable, stage of disease. Recent studies documenting as much as two decades ‘lead time’ from the initiation of pancreatic neoplasia to the onset of metastatic disease further underscores the window of opportunity for early detection strategies [3].

It is now well established that pancreatic cancer arises through a series of noninvasive precursor lesions, which culminate in invasive neoplasia [4]. The most common precursor lesion is microscopic in nature, and is denoted as pancreatic intraepithelial neoplasia or PanIN [5]. With rare exceptions, PanINs are undetectable by radiological imaging and are only observed histologically in surgical resection specimens, typically in the parenchyma adjacent to invasive adenocarcinoma. In contrast, the two macroscopic cystic precursor lesions of invasive pancreatic cancer, intraductal papillary mucinous neoplasm (IPMN) and mucinous cystic neoplasm (MCN) – are detectable with abdominal imaging [6,7]. Despite clinical and pathological distinctions, both cystic precursor lesions are characterized by a mucin-producing neoplastic epithelium, which distinguishes them from other so-called ‘nonmucinous’ cystic lesions arising in the pancreas that harbor minimal neoplastic potential [7,8,9]. Once a pancreatic ‘pseudocyst’ has been excluded, the most common nonmucinous cyst of the pancreas is the serous cystadenoma (SCA). Other less common nonmucinous cysts include lymphangiomas and hemangiomas, lymphoepithelial cysts, duplication cysts, and rarely, cystic degeneration within a well-differentiated pancreatic neuroendocrine tumor [8,9]. Clearly, a biologically and clinically diverse and somewhat confounding array of clinical entities can produce cysts in the pancreas.

The most frequent cystic lesion in the pancreas is a pancreatic pseudocyst (>90%), while SCAs, MCNs and IPMNs account for less than 10%. Of note, most pancreatic pseudocysts are symptomatic; however, and once these are excluded, the majority of asymptomatic cysts of the pancreas are comprised of the remaining three entities listed above. In recent years, the expanded use of abdominal imaging has resulted in the detection of an ever increasing number of asymptomatic pancreatic cysts (incidentalomas) [6,10]. Histological analyses of surgically resected asymptomatic cysts from several independent series suggest that as many as half are mucin-producing precursor lesions (either IPMNs or MCNs) [11,12,13]. Thus, detection of an asymptomatic cyst in the pancreas represents a unique opportunity for secondary prevention of an invasive pancreatic cancer. At the same time, the dictum of ‘primum non nocere’ mandates that clinicians make every attempt to spare patients with clinically insignificant cysts the rigors of an unnecessary pancreatic surgery. Irrespective of their histogenesis, certain cystic lesions of the pancreas require surgical resection, either because they become symptomatic, or because of suggestive radiological features of an underlying carcinoma [14,15]. Nonetheless, a substantial proportion of asymptomatic cysts present a continuing challenge for gastroenterologists and surgeons alike vis-à-vis their best course of diagnosis and management.

The most important clinical tools available for the diagnosis of pancreatic cystic lesions are cross-sectional imaging, endoscopic ultrasound (EUS), and cyst fluid analysis [16]. Even as EUS is rapidly becoming the imaging modality of choice for a variety of pancreatic diseases, this modality may not be sufficiently reliable in differentiating amongst various cystic lesions. The reported accuracy of EUS imaging alone for differentiating benign from premalignant or malignant pancreatic cysts ranges from 40 to 93% [17,18,19]. In addition to imaging, aspiration of cyst fluid contents can be conveniently and safely performed by EUS-guided fine-needle aspiration, which provides material for cytopathology and the assessment of tumor markers. Unfortunately cystic lesions, in general, are fairly hypocellular, such that the sensitivity of cytology examination remains low (∼50%) despite a high specificity [20,21,22]. Thus, there is an unmet need for ancillary biomarkers in cyst fluid material that can provide additional and reliable distinction between mucinous cystic precursors of pancreatic cancer versus clinically insignificant nonmucinous lesions.

microRNAs (miRNAs) are a diverse class of 18–24 nucleotide noncoding RNA molecules, whose principal function is to regulate the stability and translation of nuclear mRNA transcripts [23,24]. Aberrant miRNA expression is widespread in human cancers, including pancreatic adenocarcinomas, as we and others have demonstrated [25,26,27,28]. Recent studies from our group [29,30], and others [31], have also established aberrant miRNA expression in precursor lesions of pancreatic cancer, reinforcing the notion that abnormal miRNA expression can be observed early during multistep carcinogenesis. In addition, cancer-associated miRNAs, which are shed by neoplastic cells, are readily detectable in the peripheral circulation of patients [32], and are emerging as candidate biomarkers for the early detection of cancer [33,34,35]. We postulated that aberrantly expressed miRNAs generated by cystic precursor lesions of pancreatic adenocarcinoma might similarly be released into the cyst fluid, and thus be utilized as ancillary diagnostic markers. In this pilot study, we demonstrate the feasibility of utilizing pancreatic cyst fluid samples as a substrate for miRNA detection, and confirm the presence of aberrantly expressed miRNAs in these samples. We also identify miR-21 as a promising biomarker for the distinction of mucinous precursor lesions (IPMNs and MCNs) from other nonmucinous cysts of the pancreas.

 

goto top of outline Materials and Methods

goto top of outline Pancreatic Cyst Fluid Collection

Pancreatic cyst fluid specimens were obtained from a series of 54 patients who underwent surgical resection at the Johns Hopkins Hospital during the period January 2008 to February 2009, with an underlying diagnosis of a pancreatic cyst. Cyst fluid specimens were obtained ex vivo by aspiration in the Surgical Pathology suite, shortly after the surgical removal of cystic lesions. Aliquots were made from the cyst fluid, and were stored at –80°C until further analysis. A minimum of 400 µl of cyst fluid was used for RNA extraction (described below), and thus 14 samples with volumes <400 µl were not included for analysis. Of the remaining 40 cyst fluid specimens, histological validation of the cyst lining was available for each case (‘gold standard’) using established diagnostic criteria [36]. This sample set included 24 cystic precursor lesions, including 14 IPMNs and 10 MCNs. Of the IPMNs, 11 were noninvasive lesions, while 3 had an associated invasive component; all of the 10 MCNs were noninvasive (table 1). The 16 nonmucinous cysts included 11 cases of SCA, and 5 additional benign cysts (two hemangiomas, and one each of a lymphangioma, lymphoepithelial cyst, and duplication cyst). The physical appearance of the cyst fluid sample is tabulated in online supplementary table 1 (for all supplementary material, see www. karger.com/doi/10.1159/000329183; some of the biospecimens obtained were exhausted, and unavailable for gross characterization). The indications for surgery in the nonmucinous cysts fell into one of two categories: either the patient was symptomatic from the underlying cyst, or preoperative imaging (abdominal computed tomography, CT, scan or magnetic resonance imaging) could not conclusively exclude a mucinous neoplasm (this was the most common cause for resection of SCAs included in our series).

TAB01
Table 1. Clinical and pathological features of pancreatic cystic lesions

goto top of outline miRNA Extraction and Quantitative Reverse Transcription PCR

After thawing at 4°C, 400 µl of cyst fluid was subjected to small RNA extraction using the mirVana™ miRNA isolation kit (Ambion/Applied Biosystems, Austin, Tex., USA) according to the manufacturer’s protocol. Quantitative reverse transcription PCR (qRT-PCR) for miRNAs was performed using pre-designed TaqMan® miRNA assays (Applied Biosystems, Foster City, Calif., USA) with the 7300 Real-Time PCR system (Applied Biosystems). The assays are two-step protocol, including reverse transcription with human mature miRNA-specific RT primers, followed by real-time PCR with miRNA specific primers, as previously described [29,30]. These assays target only the mature miRNA sequence and the precursors are not detected. We selected a panel of five miRNAs (miR-21, miR-155, miR-17-3p, miR-191, and miR-221) which were previously described as significantly overexpressed in invasive pancreatic cancers [25,26,27,28] as candidates for analysis. The noncoding RNU6B (U6 control) was used as the normalization control. Each cyst fluid sample was assessed in triplicate for any given miRNA. The relative fold expression of the miRNAs was calculated utilizing the comparative Ct (ΔCt) method [37].

goto top of outline Statistical Analysis

Statistical analyses were performed using SPSS version 11 (SPSS Inc., Chicago, Ill., USA) and R (http://cran.r-project.org/). Continuous variables are presented as mean with standard deviation (SD). The unpaired Student t test was used to compare the ΔCt values of miRNAs expressed in the mucinous versus nonmucinous cyst fluid samples, and a stringent p value <0.01 was considered statistically significant. The depiction of miRNA differential expression was generated using GraphPad Prism version 5. Receiver operating characteristic (ROC) curves were generated for each miRNA in order to calculate the area under the curve (AUC), a measure of the predictive power for accurately classifying the nature of the cystic lesion. To produce highly stringent (99%) confidence bands for each ROC curve, we implemented a bootstrap resampling procedure. That is, after calculating the mean ΔCt value for each sample, averaging over all repeated qRT-PCR measurements, we repeatedly simulated new, random datasets by sampling with replacement from these values, so that some were used repeatedly, while others left out at each iteration. The median ROC curve is shown as a solid black line in each plot, while the upper and lower bounds of the 99% confidence bands are represented by broken black lines. Target performance levels of 80% sensitivity and 50% specificity are represented by horizontal and vertical lines, respectively.

 

goto top of outline Results

goto top of outline A Subset of miRNAs Is Upregulated in the Cystic Precursor Lesions versus Nonmucinous Cysts

Using the ΔCt method [37], we identified a significantly higher relative fold expression of three miRNAs – miR-21, miR-221, and miR-17-3p – in the mucinous precursor lesions versus the nonmucinous cysts (p < 0.01; fig. 1). In the ΔCt method, a higher ΔCt value corresponds to lower expression levels, and vice versa. Thus, the mean ΔCt values for miR-21 were 9.08 (SD 2.37; 95% CI, 7.82–10.34) and 6.28 (SD 1.61; 95% CI, 5.60–6.95) in the nonmucinous versus mucinous cyst groups, respectively (p = 0.002). Similarly, the mean ΔCt values for miR-221 were 11.37 (SD 2.34; 95% CI, 10.12–12.61) and 8.38 (SD 2.78; 95% CI, 7.21–9.55) in the nonmucinous versus mucinous cyst groups, respectively (p = 0.006). Finally, the mean ΔCt values for miR-17-3p were 12.2 (SD 2.16; 95% CI, 11.05–13.35) and 9.77 (SD 2.64; 95% CI, 8.66–10.88) in the nonmucinous versus mucinous cyst groups, respectively (p = 0.001). These ΔCt values correspond to a relative fold overexpression of 7.0-, 7.9-, and 5.4-fold, respectively, for miR-21, miR-221 and miR-17-3p in the mucinous cysts versus nonmucinous lesions. The expression of miR-155 was not significantly different (mean ΔCt of 8.15 in the nonmucinous versus 5.92 in mucinous, p = 0.045), although there was a trend towards relative upregulation in the mucinous cyst group. In the examined panel, miR-191 demonstrated comparable expression profiles between the two groups (p = 0.28; data not shown). Finally, we examined whether there were any significant differences in ΔCt values between the two mucinous cystic lesions (IPMNs and MCNs), and none reached statistical significance (p values for miR-21, miR-221, miR-155, miR-17-3p, and miR-191 being 0.73, 0.92, 0.56, 0.65, and 1, respectively).

FIG01
Fig. 1. Expression profiles of miR-21, miR-221, miR-17-3p, and miR-155 in pancreatic cyst fluid samples. The indicated miRNA target was evaluated by qRT-PCR on small RNAs extracted from 16 nonmucinous and 24 mucinous cysts. Each sample was assessed in triplicate, and the Ct values for individual miRNA biomarkers were normalized to those of U6 noncoding RNA. The horizontal bars represent mean ΔCt value. The significance level is designated on the panel. Data for miR-191 are not shown.

goto top of outline Performance Characteristics for Cyst Fluid miRNAs in Differentiating between Mucinous and Nonmucinous Pancreatic Cystic Lesions

Since miR-21, miR-221 and miR-17-3p showed significant differences in expression profiles, we generated ROC curves for each of the three miRNAs in order to determine the sensitivity and specificity performance characteristics for the diagnosis of mucinous cystic lesions. As seen in figure 2, both miR-221 and miR-17-3p achieve a sensitivity of 80% at a specificity of 50%, although in each case, the lower confidence bound gives a specificity of less than 20% when the sensitivity is 80%. On the other hand, miR-21 shows very robust performance, with the entire confidence band passing through the performance target represented in the upper, left quadrant of the plot (median AUC of 0.89). In fact, the median specificity is 76%, at a sensitivity of 80%, while at the other end we achieve a remarkable sensitivity of 96% when the specificity is 50%.

FIG02
Fig. 2. Performance characteristics of miR-21, miR-221 and miR-17-3p in pancreatic cyst fluid. Target performance levels of 80% sensitivity and 50% specificity are represented by horizontal and vertical lines, respectively.

 

goto top of outline Discussion

Currently, the most accurate and noninvasive visual assessment of the pancreas can be obtained using cross-sectional imaging modalities including contrast enhanced CT and magnetic resonance imaging, as well as by EUS [16,38]. In particular, EUS not only allows for the evaluation of structural alterations within the parenchyma, but the added possibility of a simultaneous fine needle aspiration biopsy provides a unique opportunity to collect pancreatic cyst fluid, and to subsequently analyze this for cytology and other laboratory tests [39,40,41]. Cells that are shed from the cystic epithelium (and the nucleic acids and proteins released from these cells) represent a readily accessible proximate source of candidate biomarkers for evaluating the biological potential of a given cyst. Unfortunately, conventional cytology has proved to be rather unreliable in this regard, as the specimens frequently contain scant material or the biopsy samples are contaminated by tissue originating from the route traversed by the EUS needle (such as the gastric mucosa), compromising the sensitivity of the assay [41,42]. In contrast, the cyst fluid per se is considered to be an extremely promising clinical specimen for biomarker studies.

Both biochemical and molecular cyst fluid analyses are a focus of ongoing research. For example, the diagnostic value of the tumor-specific antigens secreted by the neoplastic epithelium, such as carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 and cancer antigen 125, has been analyzed in numerous studies [42,43,44,45]. Of these, cyst fluid CEA appears to have the most promising performance criteria so far in distinguishing mucinous from nonmucinous cystic lesions of the pancreas. In a cooperative cyst study, a cyst fluid CEA level >192 ng/ml had the highest AUC for differentiating mucinous from nonmucinous cystic lesions (0.79), with an accuracy that exceeded either EUS morphology or cytology [42]. A meta-analysis of 12 pancreatic cyst fluid studies reported that a CEA level >800 ng/ml had a 48% sensitivity, but as much as 98% specificity for diagnosing mucinous lesions of the pancreas [44]. Nonetheless, some limitations in the predictive value of CEA alone have recently been reported by Raval et al. [46], who found significantly elevated CEA levels (>450 ng/ml) in 3 out of 9 lymphoepithelial cysts, which harbor no precancerous potential. Another potential limitation of CEA assessment is that in most clinical laboratories a relatively large volume of cyst fluid is mandated in order to render a reliable analysis. Therefore, this assay is often not feasible in smaller cystic lesions.

Similarly, cyst fluid DNA analysis has emerged as another promising approach for pancreatic cyst classification. For example, Khalid et al. [47] measured amount and quality of DNA, and genetic alterations (somatic KRAS mutations and loss of heterozygosity, LOH, analysis with polymorphic microsatellite markers) in order to differentiate benign from malignant pancreatic cysts. In their pilot study, the combination of KRAS gene mutations paired with a LOH was highly predictive of malignancy within a pancreatic cyst. The authors validated these initial findings with a subsequent multicenter Pancreatic cyst DNA Analysis (aka PANDA) study [48]. In this trial, cyst fluid KRAS gene mutations were predictive of a mucinous cyst, while additional features such as elevated amounts of total cyst fluid DNA, and the combination of KRAS gene mutations with microsatellite LOH were predictive of malignancy. Other studies have also confirmed that combining molecular analysis with cyst fluid CEA levels has an additive value in distinguishing mucinous from nonmucinous lesions [49,50].

The objective of this study was to establish the feasibility of performing miRNA analysis in pancreatic cyst fluid specimens, as we postulated that we could discern tangible differences in miRNA expression between mucinous and nonmucinous cystic lesions. Aberrations of miRNA expression are widespread across human cancers [25,26,27,28], and as Lu et al. [51] have reported, noncoding RNA profiles can reliably classify cancer subtypes, including outperforming global coding gene expression as classifiers. We and several groups have reported recurrent miRNA alterations in pancreatic cancer, and our group was one of the first to report comparable abnormalities in noninvasive precursor lesions of ductal adenocarcinomas [29,30]. Thus, Habbe et al. [29] assessed the relative expression levels of a panel of twelve miRNAs known to be upregulated in pancreatic cancer in 15 noninvasive IPMNs, and found miR-21 (mean 12.1-fold) and miR-155 (mean 11.6-fold) to be differentially expressed, when compared to normal pancreas. These promising findings in IPMN tissues encouraged us to focus on miRNA expression in cyst fluid samples.

One of the compelling advantages of the relative short mature miRNAs is the lack of propensity for degradation in biospecimens, a feature that plagues coding mRNAs. Weber and colleagues [] 52 [] examined the spectrum of miRNAs expressed in twelve varieties of body fluids, such as plasma, saliva, tears, urine, amniotic fluid, colostrum, breast milk, bronchial lavage, cerebrospinal fluid, peritoneal fluid, pleural fluid, and seminal fluid, obtained from normal individuals. They were able to identify differential expression patterns of miRNAs amongst the various biospecimen sources. As a proof of principle, urine samples from individuals with different conditions, including pregnancy, renal cancer, and bladder cancer were analyzed, and the distinct miRNA expression profiles confirmed. Several studies, including one from our group [33,34,35], have now identified aberrant circulating miRNAs in the serum of patients with cancer. In addition, aberrant miRNAs have been identified in aspiration cytology specimens and shown to be useful in distinguishing pancreatic cancer from chronic pancreatitis [53].

We assessed the relative expression of five miRNAs (mIR-21, miR-221, miR-17-3p, miR-155, and miR-191) in a panel of 40 cyst fluid samples obtained from 24 mucinous and 16 nonmucinous cysts of the pancreas. We used relatively minimal quantities of cyst fluid (400 µl) for miRNA extraction, a volume that should be amenable to aspiration from most pancreatic cystic lesions. Three of the four miRNAs (mIR-21, miR-221, and miR-17-3p) demonstrated highly significant differences in ΔCt values (p < 0.007 for all), which corresponded to a higher relative expression of 7.0-, 7.9-, and 5.4-fold, respectively, for miR-21, miR-221 and miR-17-3p in the mucinous cysts versus nonmucinous lesions. Using ROC curves, miR-21 had the best performance criteria, as assessed by a median AUC of 0.89, and a median specificity of 76% at a sensitivity of 80% in differentiating mucinous versus nonmucinous lesions. Notably, the combination of additional miRNAs with miR-21 did not further improve the AUC, underscoring the ‘primacy’ of miR-21. In light of the very few samples with associated invasive cancer (n = 3), we did not attempt to determine if miR-21, or other miRNAs, can further differentiate invasive from noninvasive lesions within the subset of mucinous precursor cysts, and this rather important question will be addressed in future cyst fluid studies. Nonetheless, the emergence of miR-21 as the most promising biomarker candidate in cyst fluid is not surprising, given its preeminent role as one of the original ‘onco-miRs’ in human neoplasia [54], and its well-documented overexpression in noninvasive precursor lesions of pancreatic cancer [29,30].

A potential criticism of this study is that we preselected four miRNAs essentially based on their aberrant expression in pancreatic adenocarcinomas, rather than by ‘forward genetics’ profiling of IPMN and MCN tissues. This could certainly have impacted the final outcome of our study, since there is no prerequisite that miRNAs altered in ductal adenocarcinomas should prima facie be abnormal in cystic precursor lesions. In fact, as prior studies have shown, IPMNs and MCNs harbor certain genetic differences when compared to ‘usual’ ductal adenocarcinomas, prominent amongst them being mutations of the PIK3CA and STK11 genes, and the retention of Smad4 function until fairly late in their multistep progression [55,56,57,58]. Thus, an unbiased miRNA profiling study might reveal additional candidates besides miR-21 that could enhance the assay sensitivity and specificity, likely as a multiplex miRNA panel on cyst fluid. Another shortcoming of this study is the absence of concomitant CEA levels in the samples; however, our intent was to maximize available cyst fluid volumes for RNA extraction and the requirements for current CEA assays (∼1 ml) would have depleted many of the study cases from miRNA analysis. Finally, this study was conducted on cyst fluid samples obtained from surgical resection specimens, since our intent was to ensure that we have confirmed histopathology on all cysts. A prospective trial of patients with pancreatic cysts where cyst fluid samples are obtained by EUS prior to therapeutic stratification will help cement the role of miRNAs as a diagnostic biomarker.

In conclusion, we present a pilot study demonstrating the feasibility of miRNA analysis using pancreatic cyst fluid as a substrate. Our study affirms that as little as 400 µl of pancreatic cyst fluid contains sufficient nucleic acids to interrogate at least a limited panel of five miRNAs, and that such analysis can help differentiate mucinous from nonmucinous pancreatic cystic lesions based on the level of expression for miR-21. Future tissue profiling studies will help optimize the miRNA ‘panel’ that needs to be selected for improving the performance criteria of a cyst fluid-based assay, and determine how miRNA analysis compares with other modalities such as tumor-specific antigens and mutant DNA.

 

goto top of outline Acknowledgements

Supported by the NCI SPORE in GI Cancers (P50CA062924), the Sol Goldman Pancreatic Cancer Research Center, and the Michael Rolfe Foundation for Pancreatic Cancer Research. Hanno Matthaei was supported by a fellowship grant by Deutsche Krebshilfe e.V., Bonn, Germany.


 goto top of outline References
  1. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin 2010;60:277–300.
  2. Maitra A, Hruban RH: Pancreatic cancer. Annu Rev Pathol 2008;3:157–188.
  3. Yachida S, Jones S, Bozic I, et al: Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010;467:1114–1117.
  4. Maitra A, Fukushima N, Takaori K, Hruban RH: Precursors to invasive pancreatic cancer. Adv Anat Pathol Mar 2005;12:81–91.
  5. Hruban RH, Adsay NV, Albores-Saavedra J, et al: Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 2001;25:579–586.
  6. Singh M, Maitra A: Precursor lesions of pancreatic cancer: molecular pathology and clinical implications. Pancreatology 2007;7:9–19.
  7. Adsay NV: Cystic neoplasia of the pancreas: pathology and biology. J Gastrointest Surg 2008;12:401–404.
  8. Basturk O, Coban I, Adsay NV: Pancreatic cysts: pathologic classification, differential diagnosis, and clinical implications. Arch Pathol Lab Med 2009;133:423–438.
  9. Garcea G, Ong SL, Rajesh A, et al: Cystic lesions of the pancreas. A diagnostic and management dilemma. Pancreatology 2008;8:236–251.
  10. Di Magno EP: The pancreatic cyst incidentaloma: management consensus? Clin Gastroenterol Hepatol 2007;5:797–798.

    External Resources

  11. Fernandez-del Castillo C, Targarona J, Thayer SP, Rattner DW, Brugge WR, Warshaw AL: Incidental pancreatic cysts: clinicopathologic characteristics and comparison with symptomatic patients. Arch Surg 2003;138:427–423.
  12. Kiely JM, Nakeeb A, Komorowski RA, Wilson SD, Pitt HA: Cystic pancreatic neoplasms: enucleate or resect? J Gastrointest Surg 2003;7:890–897.

    External Resources

  13. Winter JM, Cameron JL, Lillemoe KD, et al: Periampullary and pancreatic incidentaloma: a single institution’s experience with an increasingly common diagnosis. Ann Surg 2006;243:673–680.
  14. Tanaka M, Chari S, Adsay V, et al: International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 2006;6:17–32.
  15. Ferrone CR, Correa-Gallego C, Warshaw AL, et al: Current trends in pancreatic cystic neoplasms. Arch Surg 2009;144:448–454.
  16. Khalid A, Brugge W: ACG practice guidelines for the diagnosis and management of neoplastic pancreatic cysts. Am J Gastroenterol 2007;102:2339–2349.
  17. Hutchins G, Draganov PV: Diagnostic evaluation of pancreatic cystic malignancies. Surg Clin North Am 2010;90:399–410.

    External Resources

  18. Scheiman JM: Management of cystic lesions of the pancreas. J Gastrointest Surg 2008;12:405–407.
  19. Visser BC, Muthusamay VR, Mulvihill SJ, Coakley F: Diagnostic imaging of cystic pancreatic neoplasms. Surg Oncol 2004;13:27–39.
  20. Ryu JK, Woo SM, Hwang JH, et al: Cyst fluid analysis for the differential diagnosis of pancreatic cysts. Diagn Cytopathol 2004;31:100–105.
  21. Frossard JL, Amouyal P, Amouyal G, et al: Performance of endosonography-guided fine needle aspiration and biopsy in the diagnosis of pancreatic cystic lesions. Am J Gastroenterol 2003;98:1516–1524.
  22. Pitman MB, Lewandrowski K, Shen J, Sahani D, Brugge W, Fernandez-del Castillo C: Pancreatic cysts: preoperative diagnosis and clinical management. Cancer Cytopathol 2010;118:1–13.
  23. Bartels CL, Tsongalis GJ: MicroRNAs: novel biomarkers for human cancer. Clin Chem 2009;55:623–631.
  24. Croce CM, Calin GA: miRNAs, cancer, and stem cell division. Cell 2005;122:6–7.
  25. Szafranska AE, Davison TS, John J, et al: MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 2007;26:4442–4452.
  26. Lee EJ, Gusev Y, Jiang J, et al: Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer 2007;120:1046–1054.
  27. Bloomston M, Frankel WL, Petrocca F, et al: MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 2007;297:1901–1908.
  28. Kent OA, Mullendore M, Wentzel EA, et al: A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells. Cancer Biol Ther 2009;8:2013–2024.
  29. Habbe N, Koorstra JB, Mendell JT, et al: MicroRNA miR-155 is a biomarker of early pancreatic neoplasia. Cancer Biol Ther 2009;8:340–346.
  30. Ryu JK, Hong SM, Karikari CA, Hruban RH, Goggins MG, Maitra A: Aberrant MicroRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma. Pancreatology 2010;10:66–73.
  31. du Rieu MC, Torrisani J, Selves J, et al: MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions. Clin Chem 2010;56:603–612.
  32. Mitchell PS, Parkin RK, Kroh EM, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008;105:10513–10518.
  33. Li A, Omura N, Hong SM, et al: Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. Cancer Res 2010;70:5226–5237.
  34. Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X: Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 2010;127:118–126.
  35. Lodes MJ, Caraballo M, Suciu D, Munro S, Kumar A, Anderson B: Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS One 2009;4:e6229.

    External Resources

  36. Hruban RH, Klimstra DS, Pitman MB: Tumors of the Pancreas. Washington, American Registry of Pathology, 2006.
  37. Schmittgen TD, Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008;3:1101–1108.
  38. Brugge WR: Role of endoscopic ultrasound in the diagnosis of cystic lesions of the pancreas. Pancreatology 2001;1:637–640.
  39. Das A, Ngamruengphong S, Nagendra S, Chak A: Asymptomatic pancreatic cystic neoplasm: a cost-effectiveness analysis of different strategies of management. Gastrointest Endosc 2009;70:690–699.
  40. Canto MI: Strategies for screening for pancreatic adenocarcinoma in high-risk patients. Semin Oncol 2007;34:295–302.

    External Resources

  41. Thosani N, Thosani S, Qiao W, Fleming JB, Bhutani MS, Guha S: Role of EUS-FNA-based cytology in the diagnosis of mucinous pancreatic cystic lesions: a systematic review and meta-analysis. Dig Dis Sci 2010;55:2756–2766.
  42. Brugge WR, Lewandrowski K, Lee-Lewandrowski E, et al: Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst study. Gastroenterology 2004;126:1330–1336.
  43. Pitman MB, Lewandrowski K, Shen J, Sahani D, Brugge W, Fernandez-del Castillo C: Pancreatic cysts: preoperative diagnosis and clinical management. Cancer Cytopathol 2010;118:1–13.
  44. van der Waaij LA, van Dullemen HM, Porte RJ: Cyst fluid analysis in the differential diagnosis of pancreatic cystic lesions: a pooled analysis. Gastrointest Endosc 2005;62:383–389.
  45. Leung KK, Ross WA, Evans D, et al: Pancreatic cystic neoplasm: the role of cyst morphology, cyst fluid analysis, and expectant management. Ann Surg Oncol 2009;16:2818–2824.
  46. Raval JS, Zeh HJ, Moser AJ, et al: Pancreatic lymphoepithelial cysts express CEA and can contain mucous cells: potential pitfalls in the preoperative diagnosis. Mod Pathol 2010;23:1467–1476.
  47. Khalid A, McGrath KM, Zahid M, et al: The role of pancreatic cyst fluid molecular analysis in predicting cyst pathology. Clin Gastroenterol Hepatol 2005;3:967–973.
  48. Khalid A, Zahid M, Finkelstein SD, et al: Pancreatic cyst fluid DNA analysis in evaluating pancreatic cysts: a report of the PANDA study. Gastrointest Endosc 2009;69:1095–1102.
  49. Shen J, Brugge WR, Dimaio CJ, Pitman MB: Molecular analysis of pancreatic cyst fluid: a comparative analysis with current practice of diagnosis. Cancer Cytopathol 2009;117:217–227.

    External Resources

  50. Sawhney MS, Devarajan S, O’Farrel P, et al: Comparison of carcinoembryonic antigen and molecular analysis in pancreatic cyst fluid. Gastrointest Endosc 2009;69:1106–1110.

    External Resources

  51. Lu J, Getz G, Miska EA, et al: MicroRNA expression profiles classify human cancers. Nature 2005;435:834–838.
  52. Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, Galas DJ, Wang K: The microRNA spectrum in 12 body fluids. Clin Chem 2010;56:1733–1741.
  53. Szafranska AE, Doleshal M, Edmunds HS, et al: Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues. Clin Chem 2008;54:1716–1724.
  54. Cho WC: OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer 2007;6:60.
  55. Schonleben F, Qiu W, Ciau NT, et al: PIK3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas. Clin Cancer Res 2006;12:3851–3855.
  56. Sato N, Rosty C, Jansen M, et al: STK11/LKB1 Peutz-Jeghers gene inactivation in intraductal papillary-mucinous neoplasms of the pancreas. Am J Pathol 2001;159:2017–2022.
  57. Iacobuzio-Donahue CA, Klimstra DS, Adsay NV, et al: Dpc-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas: comparison with conventional ductal adenocarcinomas. Am J Pathol 2000;157:755–761.
  58. Iacobuzio-Donahue CA, Wilentz RE, Argani P, et al: Dpc4 protein in mucinous cystic neoplasms of the pancreas: frequent loss of expression in invasive carcinomas suggests a role in genetic progression. Am J Surg Pathol 2000;24:1544–1548.

 goto top of outline Author Contacts

Anirban Maitra, MBBS
Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center
Johns Hopkins University School of Medicine
1550 Orleans Street, Room 345, Baltimore, MD 21231 (USA)
Tel. +1 410 955 3511, E-Mail amaitra1@jhmi.edu


 goto top of outline Article Information

Received: March 7, 2011
Accepted after revision: May 6, 2011
Published online: July 12, 2011
Number of Print Pages : 8
Number of Figures : 2, Number of Tables : 1, Number of References : 58
Additional supplementary material is available online - Number of Parts : 1


 goto top of outline Publication Details

Pancreatology

Vol. 11, No. 3, Year 2011 (Cover Date: September 2011)

Journal Editor: Apte M.V. (Sydney, NSW)
ISSN: 1424-3903 (Print), eISSN: 1424-3911 (Online)

For additional information: http://www.karger.com/PAN


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.